Famciclovir — Membership Pricing

Other medications in Infections

• Fluconazole
• Foscarnet
• Fosfomycin
• Ganciclovir
• Imipenem-Cilastatin
• Isoniazid
• Itraconazole
• Ketoconazole

About Famciclovir

Famciclovir is an effective antiviral medication used to treat a range of viral infections, including herpes zoster (shingles), genital herpes, and cold sores. If you've been prescribed famciclovir, understanding its role and how to manage its cost is key. TheDrugClub is dedicated to helping members access their essential medications, including famciclovir, at more affordable prices.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Famciclovir is approved for (FDA label)

Famciclovir tablet, a prodrug of penciclovir, is a deoxynucleoside analog DNA polymerase inhibitor indicated for: Immunocompetent Adult Patients ( 1.1 ) • Herpes labialis (cold sores) o Treatment of recurrent episodes • Genital herpes o Treatment of recurrent episodes o Suppressive therapy of recurrent episodes • Herpes zoster (shingles) Human Immunodeficiency Virus (HIV)-Infected Adult Patients ( 1.2 ) • Treatment of recurrent episodes of orolabial or genital herpes Limitation of Use The efficacy and safety of famciclovir tablets have not been established for: • Patients with first episode of genital herpes • Patients with ophthalmic zoster • Immunocompromised patients other than for the treatment of recurrent episodes of orolabial or genital herpes in HIV-infected patients • Black and African American patients with recurrent genital herpes 1.1 Immunocompetent Adult Patients Herpes labialis (cold sores): Famciclovir tablets are indicated for the treatment of recurrent herpes labialis in adult patients.

Source: Read the full FDA label on DailyMed. Label effective date: July 21, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Famciclovir (FDA label)

Famciclovir tablets are available in 3 strengths: •125 mg : Off white, round, biconvex, film coated tablets, debossed with 'I' on one side and '50' on the other side • 250 mg: Off white, round, biconvex, film coated tablets, debossed with 'I' on one side and '49' on the other side • 500 mg: Off white, oval, film coated, biconvex tablets, debossed with 'I' on one side and '48' on the other side Tablets: 125 mg, 250 mg, 500 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 5723f50e-b0fa-65f0-e063-6294a90a350f. SPL document ID: 5723f51d-d8b3-2a59-e063-6394a90a9328. Label effective date: July 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Famciclovir (FDA label)

Acute renal failure is discussed in greater detail in other sections of the label [see Warnings and Precautions ( 5 )]. The most common adverse events reported in at least 1 indication by greater than 10% of adult patients treated with famciclovir are headache and nausea.

Source: FDA prescribing information (DailyMed). Set ID: 5723f50e-b0fa-65f0-e063-6294a90a350f. SPL document ID: 5723f51d-d8b3-2a59-e063-6394a90a9328. Label effective date: July 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Famciclovir (FDA label)

Famciclovir tablets are contraindicated in patients with known hypersensitivity to the product, its components, or Denavir ® (penciclovir cream). Known hypersensitivity to the product, its components, or Denavir ® (penciclovir cream). ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 5723f50e-b0fa-65f0-e063-6294a90a350f. SPL document ID: 5723f51d-d8b3-2a59-e063-6394a90a9328. Label effective date: July 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Famciclovir (FDA label)

Acute renal failure: May occur in patients with underlying renal disease who receive higher than recommended doses of famciclovir for their level of renal function. Reduce dosage in patients with renal impairment. ( 2.3 , 8.6 ) 5.1 Acute Renal Failure Cases of acute renal failure have been reported in patients with underlying renal disease who have received inappropriately high doses of famciclovir for their level of renal function. Dosage reduction is recommended when administering famciclovir to patients with renal impairment [see Dosage and Administration ( 2.3 ), Use in Specific Populations ( 8.6 )].

Source: FDA prescribing information (DailyMed). Set ID: 5723f50e-b0fa-65f0-e063-6294a90a350f. SPL document ID: 5723f51d-d8b3-2a59-e063-6394a90a9328. Label effective date: July 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Famciclovir (FDA label)

Probenecid: May increase penciclovir levels. Monitor for evidence of penciclovir toxicity. (7.2) 7.1 Potential for Famciclovir to Affect Other Drugs The steady-state pharmacokinetics of digoxin were not altered by concomitant administration of multiple doses of famciclovir (500 mg three times daily). No clinically significant effect on the pharmacokinetics of zidovudine, its metabolite zidovudine glucuronide, or emtricitabine was observed following a single oral dose of 500 mg famciclovir coadministered with zidovudine or emtricitabine. An in vitro study using human liver microsomes suggests that famciclovir is not an inhibitor of CYP3A4enzymes. 7.2 Potential for Other Drugs to Affect Penciclovir No clinically significant alterations in penciclovir pharmacokinetics were observed following single-dose administration of 500 mg famciclovir after pretreatment with multiple doses of allopurinol, cimetidine, theophylline, zidovudine, promethazine, when given shortly after an antacid (magnesium and aluminum hydroxide), or concomitantly with emtricitabine.

Source: FDA prescribing information (DailyMed). Set ID: 5723f50e-b0fa-65f0-e063-6294a90a350f. SPL document ID: 5723f51d-d8b3-2a59-e063-6394a90a9328. Label effective date: July 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.